The Cancer Letter

Inside information on cancer research and drug development

Conversation with The Cancer Letter

Maha Hussain: OS isn’t a practical endpoint in the context where patients are likely to live 10 years or more

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

As a veteran of the FDA Oncologic Drugs Advisory Committee, Maha Hussain took part in the group’s past discussions on treatment options for men with non-metastatic castration-resistant prostate cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

Byline
Paul Goldberg
Editor & Publisher
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account